#154189

del52 hDMD/mdx mouse

Cat. #154189

del52 hDMD/mdx mouse

Cat. #: 154189

Sub-type: Mouse

Availability: 8-10 weeks

Disease: Duchenne muscular dystrophy

Model: Transgenic

This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.

Contributor

Inventor: Annemieke Aartsma-Rus

Institute: Leiden University and Leiden University Medical Center

Tool Details
Target Details
References

Tool Details

*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)

  • Tool name: del52 hDMD/mdx mouse
  • Alternate name: Dystrophin, Muscular Dystrophy, Duchenne And Becker Types, DXS164, DXS26, DXS23, DXS239, DXS268, DXS269, DXS27, DXS272
  • Research fields: Cell biology;Drug development
  • Tool sub type: Mouse
  • Disease: Duchenne muscular dystrophy
  • Model: Transgenic
  • Conditional: No
  • Description: Duchenne muscular dystrophy (DMD) is a muscle-wasting disease in which muscle is continuously damaged, resulting in loss of muscle tissue and function. Antisense-mediated exon skipping is a promising therapeutic approach for DMD which uses sequence specific antisense oligonucleotides (AONs) to reframe disrupted dystrophin transcripts. As AONs function in a sequence specific manner, human specific AONs cannot be tested in the current mdx mouse model for DMD as it carries a mutation in the murine Dmd gene. In order to model the human disease more accurately we generated a mutant mouse model carrying the human DMD gene integrated in the mouse genome on an mdx background. The human DMD gene carries a deletion of exon 52 the mutation hotspot found in human disease. We also generated the control mouse for this model which carries full length human DMD (Cat No:154187) The line has NO dystrophin expression.
  • Phenotype: #NAME?
  • Strain: C57BL/6
  • Production details: The targeting vector (pGem-del52) was built on the backbone of the pGEM-T-easy vector (Promega). The targeting arms were generated by PCR using genomic DNA of the hDMD/mdx mouse ES cell line containing the complete hDMD gene as template. Intron 51 and 52 targeting arms were 3040 and 3134 bp long respectively. The negative selection marker herpes simplex virus thymidine kinase (HSV TK) was isolated from the pKO-SelectTK plasmid whereas the positive selection marker blasticidin, flanked by LoxP sites, was isolated from the pSVBsdX1 plasmid. The targeting arms and selection markers were PCR generated using the Expand Long Template PCR system of Roche. To facilitate cloning of the PCR isolated units, restriction enzyme digestion sites were added to the primers at the 5'end. The individual units were first cloned in the pCRII-blunt TOPO vector using the Zero Blunt TOPO PCR Cloning Kit and Sanger sequence verified prior to cloning in the destination vector. The linearized targeting construct (25 ug) was mixed with 50ug TALEN DNA and in a 1:2 ratio mixed with Lipofectamine 2000 according to the supplier's manual in KO-DMEM medium without supplements. Recombinant hDMD/mdx ES cells were injected in C57BL/6J blastocysts, which were subsequently transplanted in pseudo-pregnant foster mice.
  • Additional notes: This strain has 2 copies of the gene inserted in a tail to tail orientation for each allele. So the homozygous strain has 4 copies – each with an exon 52 deletion.

Target Details

  • Target: DMD

References

  • Veltrop et al. 2018. PLoS One. 13(2):e0193289. PMID: 29466448